The overall goal of this proposal is to expand the capability for molecular analyses of formalin fixed paraffin-embedded (FFPE) specimens through the use of whole transcriptome profiling with next generation sequencing technology (RNA-Seq). An end-to-end strategy will be developed that includes both experimental and analytical methods to address challenges specific to FFPE samples. This will enable the confident application of RNA-Seq to FFPE material to accurately profile: 1) transcriptional expression, 2) somatic mutations, and 3) chromosomal rearrangements. The strategy for the comprehensive workflow also includes resolving analysis challenges for FFPE RNA- Seq, including developing new bioinformatics tools to enhance the identification of SNV and chromosomal rearrangements. The primary aims of this Phase I application are:
Aim 1. Develop a rigorous qualification assay for FFPE RNA that is predictive of sequencing quality.
Aim 2. Develop bioinformatics analysis pipeline tailored to FFPE RNA-Seq. Upon the successful completion of these aims, a comprehensive workflow will be established which includes optimized experimental methods and bioinformatics tools to enable use of RNA-Seq for the unbiased discovery of biomarkers. In Phase II, RNA-Seq capabilities will be expanded to further develop and optimize methods, and validate the comprehensive workflow with oncology specimens. This project aligns with Asuragen's expertise and ongoing mission to develop leading-edge bioinformatics tools and to provide high quality NGS assays and NGS products for research and clinical applications.

Public Health Relevance

We will develop a novel quality control assay and bioinformatics methods to improve the capability for molecular analyses of banked frozen or fixed tissues. This research will provide solutions for detecting genetic information using Next Generation Sequencing for analysis of archived tissue samples that have been collected and stored from clinical, environmental health, and toxicology studies.

National Institute of Health (NIH)
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
Application #
Study Section
Special Emphasis Panel (ZES1)
Program Officer
Shaughnessy, Daniel
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Asuragen, Inc.
United States
Zip Code